Finepoint Capital LP holds a concentrated book of 6 stocks worth $417.1M as of Q1 2026 (disclosed May 14, 2026, a ~45-day 13F lag). This quarter they trimmed Qxo Inc. Their largest long position is Qxo Inc at 65% of the equity book. They also disclosed $1.5B in put options (a bearish bet), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1608126/holdings"
Use Arkolith to show Finepoint Capital LP's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Finepoint Capital LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| UBS Group AG | 6 / 6 | $327.4M |
| MORGAN STANLEY | 5 / 6 | $1.5B |
| GEODE CAPITAL MANAGEMENT, LLC | 5 / 6 | $250.6M |
| BANK OF AMERICA CORP /DE/ | 5 / 6 | $86.5M |
| GOLDMAN SACHS GROUP INC | 5 / 6 | $64.5M |
| SBI Securities Co., Ltd. | 5 / 6 | $32.5M |
| ROYAL BANK OF CANADA | 5 / 6 | $28.2M |
| CITIGROUP INC | 5 / 6 | $18.7M |
Ranked by how many of Finepoint Capital LP's top 6 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Qxo Inc COM NEW | $269.1M | 13.86M | 64.5% | ▼−35% Reduced · −7.3M sh | |
| 2 | Rxo Inc COMMON STOCK | $147.3M | 10.07M | 35.3% | ▲+7.3% Added · +685K sh | |
| 3 | Aleanna Inc *W EXP 12/13/202 | $397K | 490.0K | 0.1% | —Held | |
| 4 | Aleanna Inc COM CL A | $230K | 27.7K | 0.1% | —Held | |
| 5 | Moneyhero Limited *W EXP 09/13/202 | $76K | 895.0K | 0.0% | —Held | |
| 6 | Calidi Biotherapeutics Inc COM | $249 | 1.0K | 0.0% | —Held |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | SS SPDR S&P 500 ETF TRUST-USSPY | $685.9M | 1.1M |
| PUT · bearish | ISHARES SEMICONDUCTOR ETFSOXX | $483.1M | 1.5M |
| PUT · bearish | INVESCO QQQ TRUST SERIES 1QQQ | $366.4M | 635K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 14, 2026 | 9 | $2.0B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 9 | $2.0B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 13, 2025 | 9 | $1.7B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 13, 2025 | 10 | $1.4B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 | 25 | $1.3B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 13, 2025 | 26 | $1.6B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 13, 2024 | 26 | $1.4B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 13, 2024 | 25 | $352.3M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 14, 2024 | 26 | $389.9M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 13, 2024 | 27 | $317.0M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 13, 2023 | 30 | $200.8M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 11, 2023 | 37 | $289.1M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 12, 2023 | 38 | $261.8M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 13, 2023 | 44 | $309.3M | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 10, 2022 | 57 | $304.0M | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 12, 2022 | 60 | $289.2M | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 13, 2022 | 63 | $300.8M | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 11, 2022 | 71 | $390.1M | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 12, 2021 | 74 | $585.7M | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 13, 2021 | 43 | $533.4M | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 14, 2021 | 1 | $0 | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 12, 2021 | 1 | $2.5M | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 13, 2020 | 1 | $83.1M | 13F-HR |
| Q2 2020 | Jun 30, 2020 | Aug 13, 2020 | 1 | $0 | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.